nanoparticles use in vaccine transfer

1. Rimsha Farooq(BBS153009)
Syeda Rehab
Gillani(BBS153012)

3. DEFINITION OF
NANOPARTICLES
Nanoparticles are
particles between 1
and 100 nanometers
(nm) in size with a
surrounding
interfacial layer.

4. A vaccine is a biological
preparation that
provides active
acquired immunity to a
particular disease.
DEFINITION OF
VACCINE

5. NANOPARTICLES AS VACCINE
DELIVERY VEHICLES
•The vaccine antigen
is either encapsulated
within or decorated
onto the surface of the
NP.
•Conjugation of
antigens onto NPs

6. PREPARATION OF NANO
PARTICLES
VLPs can be engineered
to express additional
proteins either by fusing
these proteins to the
particle or by expressing
multiple antigens.
VLPS

7. PREPARATION OF NANO
PARTICLES
Liposomes
Liposomes are self-
assembling but consist
of a phospholipids
bilayer shell with an
aqueous core

8. NANOPARTICLES AS VACCINE
DELIVERY VEHICLES
ISCOMS
Colloidal saponin containing
micelles of around 40 nm
can be used as self-
adjuvanting vaccine delivery
systems and are collectively
known as ISCOMs.

9. NANOPARTICLES AS VACCINE
DELIVERY VEHICLES
Polymeric NPs
Polymeric NPs have
attracted much attention
for their ability to deliver
drugs as well as being
biodegradable

10. NANOPARTICLES AS VACCINE
DELIVERY VEHICLES
Non degradable Nanoparticles
Generate a shell in which to
encapsulate antigens or, more
commonly, to provide a surface
for covalent attachment

11. NPS ALONG WITH
ANTIGENS

12. CHARACTERIZATION OF
NANOAPRTICLES
The size and shape of particles is
characterized using a variety of
methods including electron microscopy,
dynamic light scattering, and density
gradient centrifugation

13. VACCINE INDUCED
IMMUNITY
Depot effect at the site of
injection prolonging exposure of
the antigen to the immune system
for a better response

14. NANOPARTICLE UPTAKE AND
IMMUNITY
Found that uptake by
antigen-presenting cells is
significantly increased for
NPs.

15. LIMITATIONS
The limitations of NPs for the
delivery of vaccines range from
concerns over the toxicity of the
particles, to difficulties in
producing the materials and
presenting antigens in their
native form.

16. ONGOING RESEARCH
Despite the number of veterinary
vaccines which utilize ISCOMs,
there are uncertainties over the
toxicity of saponin-based
adjuvants and this has to date
prevented their licensure for use
in humans.

17. REFERENCES

18. REFERENCES